Yarrow Bioscience (NASDAQ:YARW) Raised to “Hold” at Wall Street Zen

Yarrow Bioscience (NASDAQ:YARW) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

YARW has been the topic of a number of other reports. BTIG Research initiated coverage on shares of Yarrow Bioscience in a research note on Monday, August 3rd. They issued a “buy” rating and a $58.00 price objective on the stock. TD Cowen initiated coverage on shares of Yarrow Bioscience in a research note on Tuesday, July 28th. They set a “buy” rating for the company. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Yarrow Bioscience presently has a consensus rating of “Buy” and a consensus price target of $58.00.

Yarrow Bioscience Stock Down 0.0%

Shares of NASDAQ:YARW opened at $36.42 on Friday. The firm has a market cap of $97.24 million, a P/E ratio of -2.49 and a beta of 1.95. Yarrow Bioscience has a 1-year low of $14.02 and a 1-year high of $46.95.

About Yarrow Bioscience

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.